Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03529422
Title Durvalumab and Tremelimumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

hypopharynx cancer

oral cavity cancer

oropharynx cancer

head and neck squamous cell carcinoma

larynx cancer

Therapies

Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.